DRUG (Bright Minds Biosciences) Short-Term Debt : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Short-Term Debt?

Bright Minds Biosciences's Short-Term Debt for the quarter that ended in Jun. 2024 was $0.00 Mil.

Bright Minds Biosciences Short-Term Debt Historical Data

The historical data trend for Bright Minds Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Short-Term Debt Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Short-Term Debt

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Debt	Get a 7-Day Free Trial														-	-	-	-	-

Bright Minds Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Bright Minds Biosciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.